Current status and trend of clinical development of orphan drugs in China

Ziling Xiang, Wengao Jiang, Bo Yan, Junhao Jiang, H ZhengOrphanet 2022 · DOI

Abstract: The growth trends illustrate the progress in clinical trial and drug development of rare diseases from 2013 to 2021. However, promoting orphan drug development is still an important issue in China; at the same time, further efforts should be made to meet the unmet needs of various disease types and balance the uneven distribution of medical resources for clinical trials on rare diseases.

Introduction

Rare diseases affect over 300 million people worldwide. Developing "orphan drugs"—pharmaceuticals specifically for these rare conditions—is notoriously difficult due to small patient populations and high R&D risks. Historically, China lacked a clear regulatory framework and an official definition for rare diseases, leading to a significant gap in available treatments compared to the US and EU. This paper tracks China’s efforts to close that gap, analyzing whether recent regulatory shifts—such as the 2018 release of China's first official "Rare Disease Catalogue"—have successfully catalyzed clinical development.

Methodology

Researchers conducted a retrospective analysis of data from the Drug Clinical Trials and Information Registration Platform (DCTIRP), managed by China’s National Medical Products Administration (NMPA). The study covered the period from January 1, 2013, to December 31, 2021. Search criteria included the 121 rare diseases listed in China’s 2018 official catalogue. Data points extracted included registration numbers, trial phases, drug types, applicant origins, and safety measures like Data Monitoring Committees (DMCs).

Growth and Composition of Clinical Trials

Clinical trial activity saw a "sharp increase" after 2018, correlating directly with the release of the first rare disease catalogue and new policies providing "green channels" for priority review. The annual number of trials grew at an average rate of 61%, with 2021 seeing a 70% increase over 2020.

Annual numbers of clinical trials of orphan drugs by study phase, highlighting the surge after 2018 and the high volume of bioequivalence studies.

A striking 46% of all trials were Bioequivalence (BE) studies, primarily used to approve generic drugs. Most of these were initiated by domestic Chinese companies. In contrast, foreign enterprises were more likely to initiate Phase III trials for original, innovative drugs.

Disease Concentration and Market Success

Research is highly concentrated among a few conditions. Just three diseases—Parkinson’s disease (young/early onset), hemophilia, and homozygote hypercholesterolemia—accounted for 65% of all trials. Conversely, 67 of the 121 officially recognized rare diseases had zero clinical trials during the study period.

Number of clinical trials for different rare diseases, showing the heavy concentration in a few specific conditions.

As of late 2021, 41 (33%) of the 124 drugs studied have successfully reached the Chinese market. Chemical drugs made up 66% of the pipeline, while biological products accounted for 34%.

Safety Oversight and Geographic Imbalance

Trials initiated by foreign companies were significantly more likely to have a Data Monitoring Committee (17% vs. 6%) and trial injury insurance (77% vs. 64%) compared to domestic trials. Furthermore, there is a significant geographic imbalance: East China hosts 41% of clinical trial units, while Northwest and Northeast China combined account for only 12%.

Conclusion

While China has made significant strides in orphan drug development, challenges remain regarding innovation versus imitation and the equitable distribution of research resources. Future policy interventions should encourage research into neglected rare diseases and incentivize the establishment of clinical trial units in underserved regions to balance medical resource distribution.

Summary updated

Abstract

The growth trends illustrate the progress in clinical trial and drug development of rare diseases from 2013 to 2021. However, promoting orphan drugs development still is an important issue in China; at the same time, further efforts should be made for meet the unmet needs of disease types and balance the uneven distribution of medical resources for clinical trial on rare diseases.
BibTeX
@inproceedings{xiang2022current,
  author = {Ziling Xiang and Wengao Jiang and Bo Yan and Junhao Jiang and H Zheng},
  title = {{Current status and trend of clinical development of orphan drugs in China}},
  booktitle = {Orphanet},
  year = {2022},
  doi = {10.1186/s13023-022-02440-4},
}
Figure